StreetInsider.com News Articles

Form SCHEDULE 13G Amphastar Pharmaceutical Filed by: DIMENSIONAL FUND ADVISORS LP

Tue, 14 Jul 2026 13:27:00 -0400

si-local-file:///var/storage/secattach/20260714/26767395.html

Form SCHEDULE 13G Amphastar Pharmaceutical Filed by: DIMENSIONAL FUND ADVISORS LP

Tue, 14 Jul 2026 13:27:00 -0400

si-local-file:///var/storage/secattach/20260714/26767395.html

Form 4 Amphastar Pharmaceutical For: Jul 09 Filed by: Pierce Anthony T

Mon, 13 Jul 2026 19:38:00 -0400

si-local-file:///var/storage/secattach/20260713/26763463.html

Form 4 Amphastar Pharmaceutical For: Jul 09 Filed by: Pierce Anthony T

Mon, 13 Jul 2026 19:38:00 -0400

si-local-file:///var/storage/secattach/20260713/26763463.html

Form 3 Amphastar Pharmaceutical For: Jul 09 Filed by: Pierce Anthony T

Mon, 13 Jul 2026 19:36:00 -0400

si-local-file:///var/storage/secattach/20260713/26763461.html

Form 3 Amphastar Pharmaceutical For: Jul 09 Filed by: Pierce Anthony T

Mon, 13 Jul 2026 19:36:00 -0400

si-local-file:///var/storage/secattach/20260713/26763461.html

Form 8-K Amphastar Pharmaceutical For: Jul 09

Mon, 13 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260713/26759181.html

Form 8-K Amphastar Pharmaceutical For: Jul 09

Mon, 13 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260713/26759181.html

FDA issues warning letter to Amphastar Pharma subsidiary over manufacturing

Wed, 08 Jul 2026 06:04:01 -0400

Amphastar Pharmaceuticals (NASDAQ: AMPH) disclosed that its subsidiary, International Medication Systems, Limited (IMS), received a warning letter from the U.S. Food and Drug Administration on July 2, 2026, related to its drug manufacturing facility in South El Monte, California.

The warning letter follows an FDA inspection of the facility conducted in December 2025, which resulted in inspectional observations recorded on an FDA Form 483. The FDA cited violations of current Good Manufacturing Practice (CGMP) regulations, specifically regarding investigation procedures, environmental monitoring and handling procedures, and manufacturing equipment.

The warning letter does not direct IMS to cease operations or restrict products from the

FDA issues warning letter to Amphastar Pharma subsidiary over manufacturing

Wed, 08 Jul 2026 06:04:01 -0400

The warning letter does not direct IMS to cease operations or restrict products from the

FDA issues warning letter to Amphastar Pharma subsidiary over manufacturing

Wed, 08 Jul 2026 06:04:01 -0400

The warning letter does not direct IMS to cease operations or restrict products from the

Form 8-K Amphastar Pharmaceutical For: Jul 02

Wed, 08 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260708/26743725.html

Form 8-K Amphastar Pharmaceutical For: Jul 02

Wed, 08 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260708/26743725.html

BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns

Mon, 29 Jun 2026 11:51:02 -0400

Investing.com -- Bank of America downgraded four U.S. biopharmaceutical companies, lowering ratings on Alkermes, Amphastar Pharmaceuticals and Biohaven to Underperform, while cutting Liquidia to Neutral, citing a combination of stretched valuations, uncertain near-term catalysts and a rebalancing of its ratings across the sector.

The brokerage said the changes reflect differing risk-reward profiles rather than a broad shift in its outlook for the industry. Three companies were downgraded due to valuation and catalyst concerns, while Liquidia's rating was reduced despite improving fundamentals because of uncertainty surrounding an upcoming patent litigation outcome.